The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi).
Kurt A. Jaeckle
No relevant relationships to disclose
David Schiff
No relevant relationships to disclose
S. Keith Anderson
No relevant relationships to disclose
Evanthia Galanis
No relevant relationships to disclose
Philip J. Stella
No relevant relationships to disclose
Patrick J. Flynn
No relevant relationships to disclose
Jann Nagina Sarkaria
No relevant relationships to disclose
Caterina Giannini
No relevant relationships to disclose
Bradley J. Erickson
No relevant relationships to disclose
Jan C Buckner
No relevant relationships to disclose